TGFB1 and disease of the tendon: Systemic inhibition of TGF‐β activity by injection of a TGF‐β neutralizing antibody or knockout of the TGF‐β type 2 receptor gene (Tgfbr2) in tenocytes efficiently blocked progression of tendinopathy.